VIRGINIA SMITH: Open Payments
NPI 1568827095 · OMAHA, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,418 in 166 payments from 18 companies in 2025. Trend: 2023 $2,359 · 2024 $1,557 · 2025 $3,418
Food & beverage: $3,418
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 34 | $785 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 26 | $576 |
| ABBVIE INC. | 26 | $422 |
| Otsuka America Pharmaceutical, Inc. | 17 | $340 |
| HARMONY BIOSCIENCES LLC | 9 | $204 |
| E.R. Squibb & Sons, L.L.C. | 5 | $199 |
| Teva Pharmaceuticals USA, Inc. | 12 | $175 |
| Axsome Therapeutics, Inc. | 8 | $151 |
| Neurocrine BioSciences, Inc. | 6 | $114 |
| Vanda Pharmaceuticals Inc. | 4 | $101 |
Products named: CAPLYTA, VRAYLAR, ARISTADA, LYBALVI, WAKIX, COBENFY, REXULTI, VIVITROL.
Industry payments across NE — which companies pay providers there.
